Schroder Investment Management Group Inhibrx, Inc. Transaction History

Schroder Investment Management Group

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$14.5 - $38.0 $1.54 Million - $4.03 Million	-106,148 Reduced 44.7%	131,295 $4.99 Million
Q3 2023 Nov 14, 2023	SELL	$15.75 - $26.31 $1.32 Million - $2.21 Million	-83,946 Reduced 26.12%	237,443 $4.36 Million
Q1 2023 May 11, 2023	SELL	$18.45 - $27.14 $990,506 - $1.46 Million	-53,686 Reduced 14.31%	321,389 $6.06 Million
Q4 2022 Feb 10, 2023	SELL	$20.18 - $33.33 $1.8 Million - $2.97 Million	-89,215 Reduced 19.22%	375,075 $9.24 Million
Q3 2022 Nov 10, 2022	BUY	$11.58 - $24.73 $2.12 Million - $4.52 Million	182,961 Added 65.03%	464,290 $8.33 Million

Q2 2022 Aug 11, 2022	BUY	$8.52 - $25.26 $49,100 - $145,573	5,763 Added 2.09%	281,329 $3.37 Million
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $3.15 Million - $6.84 Million	158,397 Added 135.19%	275,566 $6.16 Million
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $655,535 - $1.13 Million	24,506 Added 26.45%	117,169 $5.12 Million
Q3 2021 Nov 12, 2021	BUY	$25.18 - $37.81 $2.33 Million - $3.5 Million	92,663 New	92,663 $3.09 Million

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.